mRNA vaccination as a safe approach for specific protection from type I allergy
Abstract
Allergic diseases are on the increase and current therapies are lacking in efficacy and patient compliance. In recent years, the idea of prophylactic measures, especially for children at high risk for allergy, has become increasingly popular. This review summarizes the available preclinical data for protective allergy vaccines, with a focus on one of the most promising vaccine candidates; mRNA vaccines. Recently, mRNA vaccines have been rediscovered as an alternative to their more prominent counterparts, the DNA vaccines. Allergen-encoding mRNA vaccines elicit long-lasting protection from sensitization, and induce a type of immunity similar to the natural protective response that is acquired in the presence of microbial burden early in life. Owing to their excellent safety profile, they represent the ideal candidates for a vaccine that aims to protect at-risk children who have not yet been sensitized to allergens.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many of the obstacles to mRNA vaccine development have been surmounted, and recently there has been a revival in the use of nonamplifying mRNA vaccines for cancer, allergy, and gene therapy.
“However, many of the obstacles to mRNA vaccine development have been surmounted, and recently there has been a revival in the use of nonamplifying mRNA vaccines for cancer (6), allergy (7), and gene therapy (8).”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [7]
The citation lists haven’t been fetched yet
References 135 · Cited by 42
- Authors
- Weiss, R., Scheiblhofer, S., Roesler, E., Weinberger, E., & Thalhamer, J.
- Affiliations
- University of Salzburg (AT)
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2012-01
- Volume
- 11
- Issue
- 1
- Pages
- 55-67
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2104719439
- Cited by
- 42
- References
- 135
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 6 · 2014: 7 · 2013: 6 · 2012: 2
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Vaccines (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Keywords
- mRNA vaccines, allergic diseases, type I allergy, allergen immunotherapy, allergen sensitization, vulnerable children, vaccine safety, DNA vaccine
- MeSH terms
- Allergens, Humans, Hypersensitivity, RNA, Messenger, Vaccines, Synthetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
